Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy Academic Article uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Neoplasms, Hormone-Dependent
  • Prostate-Specific Antigen
  • Prostatic Neoplasms

abstract

  • To the authors' knowledge, this was the first report to demonstrate that a faster time to reach a PSA nadir after the initiation of ADT was associated with shorter survival duration in men with metastatic HSPC. These results need confirmation but may indicate that a rapid initial response to ADT indicates more aggressive disease.

publication date

  • March 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2931827

Digital Object Identifier (DOI)

  • 10.1002/cncr.24064

PubMed ID

  • 19152438

Additional Document Info

start page

  • 981

end page

  • 7

volume

  • 115

number

  • 5